key: cord-1008874-gfpvw4if authors: Fu, Winnie; Sivajohan, Brintha; McClymont, Elisabeth; Albert, Arianne; Elwood, Chelsea; Ogilvie, Gina; Money, Deborah title: Systematic review of the safety, immunogenicity, and effectiveness of COVID‐19 vaccines in pregnant and lactating individuals and their infants date: 2021-11-13 journal: Int J Gynaecol Obstet DOI: 10.1002/ijgo.14008 sha: 88ad835bd09d602b5ff3db20c203ba9fe5a68714 doc_id: 1008874 cord_uid: gfpvw4if BACKGROUND: There is significant risk of complications and vulnerability to severe COVID‐19 disease in pregnancy, yet hesitancy exists around COVID‐19 vaccination during pregnancy and lactation. OBJECTIVE: To summarize the safety, immunogenicity, and effectiveness of COVID‐19 vaccines in pregnancy and lactation. SEARCH STRATEGY: A systematic search of MEDLINE, Embase, PubMed, medRxiv, and bioRxiv. SELECTION CRITERIA: Identified original studies published on pregnant and/or lactating individuals who received one or more doses of a COVID‐19 vaccine. DATA COLLECTION AND ANALYSIS: A descriptive summary organized by safety, immunogenicity, and effectiveness outcomes of COVID‐19 vaccination in pregnancy and lactation. MAIN RESULTS: In total, 23 studies were identified. Humoral response and functional immunity were interrogated and found. Increasing placental transfer ratios in cord blood were associated with increasing time from the first vaccine dose to delivery. Safety data indicated that pregnant and lactating populations experienced vaccine‐related reactions at similar rates to the general population. No increased risk of adverse obstetrical or neonatal outcomes were reported. One study demonstrated that pregnant individuals were less likely to experience COVID‐19 when vaccinated. CONCLUSION: COVID‐19 vaccination in pregnant and lactating individuals is immunogenic, does not cause significant vaccine‐related adverse events or obstetrical and neonatal outcomes, and is effective in preventing COVID‐19 disease. However, vaccine hesitancy remains high among some pregnant and lactating individuals, particularly due to the perceived lack of data from randomized clinical trials. 14 The aim of the present review was to combine safety, immunogenicity, and effectiveness data on COVID-19 vaccines in pregnancy to provide an integrated review of a rapidly developing situation. A systematic search was conducted of MEDLINE, Embase, PubMed, medRxiv, and bioRxiv to identify original studies published on pregnant and lactating individuals who received one or more doses of a COVID-19 vaccine. For PubMed, MEDLINE, and Embase, a combination of pregnancy and lactation-related terms, vaccine-related terms, and the COVID-19 search strings developed by the Canadian Agency for Drugs and Technologies in Health were used (Appendix 1). 15 The search was conducted from September 1, 2020, to June 29, 2021, and results were restricted to the English language. For medRxiv and bioRxiv, the "medrxivr" R package was used to search preprint repository data (Appendix 1). The present study followed PRISMA guidelines and was registered on PROSPERO (CRD42021258912). Records were screened by title, abstract, and full text for inclusion. Covidence and Excel were used to record decisions. Original studies that evaluated the immunogenicity, safety, and effectiveness of COVID-19 vaccines in pregnant and lactating individuals were included. Cohort studies, case-control studies, and cross-sectional studies were included. Studies with less than 10 participants were excluded from analysis. Data extracted from studies included the following: first author; country; study design; population characteristics; vaccine type and characteristics; and study outcomes (as related to safety and immunogenicity). Data were recorded using Covidence and Excel. We assessed the quality of each study using the National Institute of Health (NIH) Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies and the NIH Quality Assessment of Case-Control Studies. Two reviewers independently screened records, extracted data, and assessed study quality. Disagreements between reviewers were resolved by consensus. Immunogenicity, safety, and effectiveness outcomes were described qualitatively. The search returned 650 unique records. After screening the titles and abstracts, 42 full texts were reviewed. Of these articles, 13 were included in the review. Ten additional pre-print and in-press articles were included, resulting in a total of 23 articles included in the review (Figure 1 ). In total, 23 studies were included in the systematic review (Table 1) . All studies were conducted in high-income countries. The majority were observational cohort studies (n = 18), followed by case-control (n = 3) and cross-sectional (n = 2) studies. Eight studies looked exclusively at participants who had received BNT162b2 The quality of each study, independently assessed by two reviewers using the National Institute of Health (NIH) Quality Assessment Tool, is presented in Tables S1 and S2. Seventeen studies evaluated and quantified the humoral response in breast milk, cord blood, and/or maternal blood after vaccination (Table 2 ). Seven studies assessed antibody titers in vaccinated maternal and cord blood. [16] [17] [18] [19] [20] [21] [22] Transfer of IgG to cord blood was noted in all studies. All studies assessed IgG to RBD and/or spike protein. Placental transfer ratios (cord blood antibody concentration/maternal serum antibody concentration) differed between and within studies. Five studies observed that increasing transfer ratios of IgG in cord blood were associated with having received the second vaccine dose before delivery, and with increasing time from the first vaccine dose to delivery. [18] [19] [20] [21] [22] In their study of 13 individuals, Gray et al. 18 20 had one participant out of 67 who received their second dose more than 10 weeks before delivery. Generally, all studies noted a positive linear relationship between placental transfer ratio 19, 20 or IgG titers in cord blood 17, 18, 21 and time since the first and/or second vaccine dose to delivery. Additionally, Gray et al. 18 noted that the time-dependent nature of transfer efficiency may only affect specific IgG subpopulations. A significant increase in transfer of IgG1 spike was correlated with increased time from dose 2 to delivery, but this correlation was not observed for IgG1 RBD. Functional antibody subpopulations were also studied. Atyeo et al., 22 in their study of seven individuals, noted that equivalent phagocytic antibodies and lower FcR binding and NK-cell activating antibodies against SARS-CoV-2 spike antigen were found in cord blood compared to maternal serum. Conversely, in the same study, Eight studies noted an increase in IgG, IgM, and/or IgA in the sera of pregnant and lactating individuals after vaccination. 16, 18, [22] [23] [24] [25] [26] [27] Gray et al. 18 observed that IgM and IgA titers were strongly in- Esteve-Paula et al. 23 18/18 (IgG-S1) 18/18 (IgG-S1) N/A Low et al. 28 10 Taken together, the studies from Friedman et al. 27 and Esteve-Palau et al. 23 suggest that peak antibody titers may occur as early as 7 days after the second dose and last as long as 28 days after the second dose. Similar to antibodies in sera, IgG, IgA, and IgM titers in breast milk also were detected after vaccination. 16 Multiple studies profiled the functional response of the antibodies produced. Neutralizing antibodies were assayed and found in maternal sera in two studies, 16, 18 cord blood in two studies, 16, 18 and breast milk in two studies. 16, 24 Collier et al. 16 ADCP and ADNP were transferred at comparable ratios after the first dose, ADCP was transferred at a higher ratio than ADNP after the second dose. Collier et al. 16 examined spike-specific T-cell responses in the peripheral blood mononuclear cells of 18 pregnant, 7 lactating, and 12 non-pregnant patients. It was noted that the percentage of spikespecific IFN-gamma production by CD4 T-cells, CD4 central mem- across all three groups. Nine different studies looked at symptom profiles in pregnant and/ or lactating patients after the first and/or second dose (Tables 3 and 4) . 16 Shimabukuro et al. 33 Bertrand et al. 32 Five studies reported on pregnancy loss and/or neonatal outcomes after maternal vaccination (Table 5) . 17, 18, 33, 37 The two studies with the largest participant sizes did not find an increased risk of pregnancy loss or adverse neonatal outcomes. Shimabukuro et al. 33 compared all reported outcomes to published incidences among the general population and found that rates of spontaneous abortion (12.6%), stillbirth (0.1%), preterm birth (9.4%), small size for gestational age (3.2%), congenital anomalies (2.2%), and neonatal death (0%) all fell within the range or lower than published incidences. Theiler et al. 37 compared a pregnant, vaccinated cohort to a pregnant, unvaccinated cohort (n = 140 vs n = 1862) and found that the adverse outcome index (a composite of adverse maternal events) did not differ by vaccination status. Only one study examined the effectiveness of the vaccine in pregnant patients. Theiler et al. 37 The present systematic review describes the current literature on the immunogenicity, safety, and effectiveness of COVID-19 vaccines in pregnant and lactating individuals. Immunogenicity data indicated that robust humoral responses were mounted in maternal sera, and transferred to cord blood and breast milk. Seroconversion was close to 100% for all studies that assessed humoral response. Functional immunity, antibody-dependent activity, and T-cell response were also interrogated and found in TA B L E 5 Pregnancy loss and neonatal outcomes after vaccination a Shimabukuro et al. 33 Beharier et al. 17 Gray et al. 18 Theiler et al. 37 Kadali et al. 34 Spontaneous Importantly, higher incidences of adverse obstetrical and neonatal outcomes were not seen in vaccinated cohorts compared to prior published incidences/unvaccinated cohorts. Due to rapid research outputs during the COVID-19 pandemic, many publications were submitted to the pre-print repositories medRxiv and bioRxiv. About half of the studies from the present review were from these repositories (n = 11) and, as such, these papers have not undergone a rigorous peer-review process. Furthermore, because many of the studies used different assays when assessing for humoral response, values reported from these studies were not comparable and could not be meta-analyzed (Table S3) . As additional immunogenicity data are published, studies with similar assays may be compared for pooled analysis. Disease severity, pregnancy outcomes, and maternal deaths among pregnant patients with severe acute respiratory syndrome coronavirus 2 infection in Washington State Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status -United States Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature Severe coronavirus infections in pregnancy: a systematic review Society of Obstetricians and Gynaecologists of Canada SOGC statement on COVID-19 vaccination in pregnancy COVID-19 vaccines while pregnant or breastfeeding American College of Obstetricians and Gynecologists. Vaccinating pregnant and lactating patients against COVID-19: practice advisory Society for Maternal-Fetal Medicine (SMFM) statement: SARS-CoV-2 vaccination in pregnancy Coronavirus disease 2019 (COVID-19) vaccines and pregnancy: what obstetricians need to know The Moderna COVID-19 (mRNA-1273) vaccine: what you need to know The Pfizer BioNTech (BNT162b2) COVID-19 vaccine: what you need to know. Accessed COVID-19 vaccine acceptance among pregnant women and mothers of young children: results of a survey in 16 countries Canadian Agency for Drugs and Technologies in Health. CADTH COVID-19 Search Strings Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study Cord blood antibodies following maternal coronavirus disease 2019 vaccination during pregnancy Antibody response to coronavirus disease 2019 (COVID-19) messenger RNA vaccination in pregnant women and transplacental passage into cord blood Efficient maternofetal transplacental transfer of anti-SARS-CoV-2 spike antibodies after antenatal SARS-CoV-2 BNT162b2 mRNA vaccination COVID-19 mRNA vaccines drive differential Fc-functional profiles in pregnant, lactating, and nonpregnant women Quantification of specific antibodies against SARS-CoV-2 in breast milk of lactating women vaccinated with an mRNA vaccine BNT162b2 COVID-19 mRNA vaccine elicits a rapid and synchronized antibody response in blood and milk of breastfeeding women Immune response during lactation after anti-SARS-CoV2 mRNA vaccine. medRxiv. 2021;1-15 Detection of SARS-CoV-2 specific IgA in the human milk of COVID-19 vaccinated, lactating health care workers The levels of SARS-CoV-2 specific antibodies in human milk following vaccination BNT162b2 vaccination induces SARS-CoV-2 specific antibody secretion into human milk with minimal transfer of vaccine mRNA. medRxiv Anti-SARS-Cov-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous Sars-Cov-2 exposure a longitudinal study SARS-CoV-2-specific antibodies in breast milk after COVID-19 vaccination of breastfeeding women The vaccine-elicited immunoglobulin profile in milk after COVID-19 mRNA-based vaccination is IgG-dominant and lacks secretory antibodies. medRxiv. 2021;1-14 Maternal and child outcomes reported by breastfeeding women following mRNA COVID-19 vaccination Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons Adverse effects of COVID-19 messenger RNA vaccines among pregnant women: a cross-sectional study on healthcare workers with detailed selfreported symptoms Breastfeeding mother-child clinical outcomes after COVID-19 vaccination Maternal and child symptoms following COVID-19 vaccination among breastfeeding mothers Pregnancy and birth outcomes after SARS-CoV-2 vaccination in pregnancy Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in pregnancy: measures of immunity and placental histopathology Systematic review of the safety, immunogenicity, and effectiveness of COVID-19 vaccines in pregnant and lactating individuals and their infants